# Carolyn Ng > Carolyn Ng is a Series B investor at TPG (Singapore) backing Biotechnology and Health Care. See 8 investments, check sizes, portfolio. Updated Aug 2026. - Type: Angel Investor - Fund: [TPG](https://shizune.co/investors/profile/texas-pacific-group) - Location: Singapore, Singapore - Total investments: 8 - Last investment: Apr 2026 - Lead investor: 25% - Last updated: Aug 2026 - LinkedIn: https://www.linkedin.com/in/carolyn-ng-18273645/ Carolyn Ng is a Series B investor at TPG in Singapore focused on Biotechnology and Health Care. Dr. Carolyn Ng is the Partner and Managing Director of TPG. She also holds a BS (Pharmacy) (First Class Honours) degree from the National University of Singapore. ## Investment focus ### Industry | Industry | Investments | Share | | --- | --- | --- | | Biotechnology | 5 | 63% | | Health Care | 4 | 50% | | Life Science | 2 | 25% | | Therapeutics | 2 | 25% | | Biopharma | 1 | 13% | 6 industries tracked in total. ### Stage | Stage | Investments | Share | | --- | --- | --- | | Series B | 2 | 25% | | Series C | 2 | 25% | | Series A | 1 | 13% | | Series D | 1 | 13% | ### Country | Country | Investments | Share | | --- | --- | --- | | United States | 4 | 50% | | Denmark | 1 | 13% | ## Investments | Company | Description | Amount | Stage | Date | Website | | --- | --- | --- | --- | --- | --- | | ADCendo | ADCendo ApS is a biotech company dedicated to developing new types of anti-cancer drugs. We focus on antibody-drug conjugates (ADCs) directed at novel targets, that have been found to be overexpressed by several cancer forms, that are all characterized by a significant unmet need for novel treatment. | $75M | Series C | Apr 14, 2026 | | | Odyssey Therapeutics | Odyssey Therapeutics is a biotechnology company pioneering the efficient development of next-generation immunomodulators and oncology medicines. Odyssey is making a transformational impact on the field of drug discovery and is accelerating the path to clinical development to drive the creation of more effective precision medicines. | $213M | Series D | Sep 10, 2025 | | | ADCendo | ADCendo ApS is a biotech company dedicated to developing new types of anti-cancer drugs. We focus on antibody-drug conjugates (ADCs) directed at novel targets, that have been found to be overexpressed by several cancer forms, that are all characterized by a significant unmet need for novel treatment. | $135M | Series B | Nov 25, 2024 | | | ADCendo | ADCendo ApS is a biotech company dedicated to developing new types of anti-cancer drugs. We focus on antibody-drug conjugates (ADCs) directed at novel targets, that have been found to be overexpressed by several cancer forms, that are all characterized by a significant unmet need for novel treatment. | $135M | Series B | Nov 25, 2024 | | | Bicara Therapeutics | Bicara Therapeutics, a wholly-owned subsidiary of Biocon based in Boston, U.S., is developing a pipeline of bifunctional antibodies that exploit the recent advances in immuno-oncology. Bicara enables access to the thriving innovation ecosystem in the U.S. which accelerates the development of cutting-edge therapies for cancer. Synergies between thescientific teams in Boston and Bengaluru will pioneer rapid and cost-effective breakthrough innovation. | $165M | Series C | Dec 12, 2023 | | | MBrace Therapeutics | MBrace Therapeutics is a privately held biopharmaceutical business dedicated to improving cancer patients' quality of life by developing antibody-drug conjugates (ADCs) against novel oncology targets. | $85M | Series B | Nov 14, 2023 | | | Twentyeight-Seven Therapeutics | Twentyeight-Seven Therapeutics is a developer of microRNAs designed to target regulatory proteins.The company's modulating RNA which are short non-coding RNAs that inhibit target gene expression by suppressing mRNA translation and promoting mRNA decay and develop small molecules that can modulate levels of miRNAs by targeting proteins thatinteract with these miRNAs, enabling users to target miRNAs are directly involved in cancer initiation, progression, and metastasis. | $15M | Series A | May 09, 2019 | | | Twentyeight-Seven Therapeutics | Twentyeight-Seven Therapeutics is a developer of microRNAs designed to target regulatory proteins.The company's modulating RNA which are short non-coding RNAs that inhibit target gene expression by suppressing mRNA translation and promoting mRNA decay and develop small molecules that can modulate levels of miRNAs by targeting proteins thatinteract with these miRNAs, enabling users to target miRNAs are directly involved in cancer initiation, progression, and metastasis. | $65M | Series A | Sep 06, 2018 | | 8 of 8 investments shown. ## Co-investors - [Lightspeed Venture Partners](https://shizune.co/investors/profile/lightspeed-venture-partners) — VC Fund, 4 deals together - [RA Capital Management](https://shizune.co/investors/profile/ra-capital-management) — VC Fund, 4 deals together - [Dawn Biopharma](https://shizune.co/investors/profile/dawn-biopharma) — VC Fund, 3 deals together - [HealthCap](https://shizune.co/investors/profile/healthcap) — VC Fund, 3 deals together - [Novo Holdings](https://shizune.co/investors/profile/novo-a-s) — VC Fund, 3 deals together - [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund, 3 deals together ## About TPG VC Fund · San Francisco, United States TPG offers a diverse range of services, including asset management, telecommunications, and cultural exchange programs. The firm manages investments across various sectors, focusing on innovative strategies to optimize returns. In telecommunications, TPG provides internet and mobile plans tailored to consumer needs, ensuring connectivity for users.Additionally, TPG facilitates cultural exchange by connecting certified English-speaking teachers with educational institutions, promoting cultural diversity in classrooms. This multifaceted approach allows TPG to address the needs of different markets while supporting both economic growth and social development. 5 contacts available at TPG. | Name | Title | Profile | | --- | --- | --- | | Akash Pradhan | Vice President | https://shizune.co/investors/profile/akash-pradhan | | Arun Agarwal | Managing Director | https://shizune.co/investors/profile/arun-agarwal-2 | | Carolyn Ng | Partner and Managing Director | https://shizune.co/investors/profile/carolyn-ng | | Chang Sun | Managing Partner | https://shizune.co/investors/profile/chang-sun | | Edward Beckley | Partner | https://shizune.co/investors/profile/edward-beckley | ## Similar investors ### Similar stage - [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund - [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund - [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund ## FAQ ### What does Carolyn Ng invest in? Carolyn Ng invests primarily in Biotechnology, Health Care and Life Science startups, most often at Series B and Series C stage. Most of the 8 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio. ### When did Carolyn Ng last invest? The most recent investment recorded for Carolyn Ng closed in Apr 2026. Shizune tracks 8 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly. ### Is Shizune's investor data accurate? Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page. # About Shizune Shizune.co is an investor database. Core features: - 48,091 startup investors (angels, VCs, accelerators, and others) - Email, phone, LinkedIn (for intros), socials, and other contact data - Updated daily from public funding news - CSV and Excel export The User can access the full database FOR FREE after signing up: shizune.co